GET DAILY SIGNALSInspireMD (NSPR) Delivers Q3 2026 Results With Narrower Loss and FDA Milestone
Key Takeaways
- InspireMD reported third quarter 2026 revenue of $2.24 million, down 11.1% from $2.52 million a year earlier.
- Net loss narrowed to $9.76 million, or $0.12 per share, from a loss of $12.71 million, or $0.17 per share, in the prior-year quarter.
- The company received FDA approval for its CGuard Prime stent for TCAR procedures, with U.S. sales expected to begin in Q4 2026.
- International revenue rose 9.1% to $2.21 million, while U.S. revenue fell sharply to $32,000 from $497,000 following an earlier product recall.
- Operating expenses declined 26.7% to $10.19 million, reflecting a restructuring that included $1.07 million in one-time costs.
- Cash, cash equivalents, and marketable securities totaled $19.25 million at quarter-end, keeping capital efficiency in focus.
Earnings Context and Why It Matters
NSPR is a medical device company focused on carotid artery disease and stroke prevention, anchored by its CGuard Prime stent system. The third quarter marks a pivotal moment because it follows a voluntary recall of the CGuard Prime 135 delivery system that halted U.S. commercial activity earlier in 2026. With U.S. revenue nearly disappearing, I am watching closely whether the company can relaunch domestically and rebuild momentum. The quarter also brought the long-awaited FDA approval of CGuard Prime for TCAR procedures, a label expansion that management has positioned as a key growth catalyst. For a development-stage company still generating net losses, the combination of regulatory progress, cost discipline, and a limited cash balance makes this report central to the investment case. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter of 2026, NSPR posted revenue of $2.242 million, a decline of 11.1% from $2.523 million in the same period last year. The result came in ahead of consensus estimates of roughly $2.0 million. Net loss was $9.762 million, or $0.12 per basic and diluted share, compared with a net loss of $12.708 million, or $0.17 per share, a year earlier. The per-share loss also beat the consensus estimate of approximately $0.15.
International revenue increased 9.1% to $2.210 million, while U.S. revenue fell to $32,000 from $497,000 in the prior-year quarter, reflecting the temporary pause in domestic commercial activity. Gross profit was $240,000, down from $864,000 a year ago. Total operating expenses decreased 26.7% to $10.193 million and included $1.074 million in restructuring charges, underscoring the company's cost-reduction efforts. For the first nine months of 2026, revenue rose 27.1% to $7.411 million.
The most significant development accompanied the financial results: FDA approval of CGuard Prime for TCAR procedures, with management indicating it expects to begin U.S. sales during the fourth quarter of 2026.
Market Reaction and Investor Sentiment
NSPR results were released after U.S. market close on November 12, 2026, so a full post-earnings trading picture has yet to develop. Heading into the print, sentiment had been weighed down by the earlier CGuard Prime recall and the resulting pause in U.S. sales, which pressured the stock through much of 2026. The narrower-than-expected loss and the top-line beat offer early positives, but the decisive catalyst for investor interpretation is the FDA's TCAR approval. That milestone directly addresses the single biggest overhang on the business — the path back to U.S. commercialization — and is likely to shape how the market prices the stock in subsequent sessions. The relatively low cash position remains a secondary concern that investors will weigh against the company's ability to execute the relaunch efficiently.
Forward Outlook and Key Factors to Monitor
The most important factor to watch is the U.S. relaunch. With FDA approval for CGuard Prime in TCAR now secured, management expects to begin domestic sales in the fourth quarter of 2026. The pace at which the commercial organization can re-engage accounts and convert demand will determine whether revenue growth resumes meaningfully in the quarters ahead.
Cost discipline will remain another key signal. The company's restructuring, including a previously announced workforce reduction, helped drive operating expenses down sharply this quarter. Investors will monitor whether those savings hold and whether gross margin improves as higher-margin U.S. sales return to the mix.
Liquidity also deserves attention. With $19.25 million in cash, cash equivalents, and marketable securities at quarter-end, the company's cash runway and any potential financing needs are likely to stay in focus. Additionally, progress on the CGUARDIANS III pivotal trial for the SwitchGuard neuroprotection system and further regulatory milestones represent longer-term catalysts that could expand the company's addressable market. As always, execution on these fronts — rather than the headline loss alone — will drive the next phase of the story.
Using AI Tools in My Research Process
From what I see, tools like Tickeron’s AI Screener can help surface relevant patterns and comparisons when evaluating names in the medical device space. I find it useful for quickly scanning technical signals and sector peers alongside fundamental updates like these earnings, which supports a more informed view without replacing deeper analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NSPR in upward trend: 10-day moving average broke above 50-day moving average on November 11, 2026
The 10-day moving average for NSPR crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on NSPR as a result. In 76 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for NSPR just turned positive on October 23, 2026. Looking at past instances where NSPR's MACD turned positive, the stock continued to rise in 39 of 49 cases over the following month. The odds of a continued upward trend are 80%.
NSPR moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where NSPR advanced for three days, in 152 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for NSPR moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 19 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NSPR broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NSPR entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.035) is normal, around the industry mean (4.142). P/E Ratio (-1.141) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.767) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. NSPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medical devices
Industry MedicalNursingServices
Advertisement